All Practice Exams

100+ Free Facharzt FMH Kinder- und Jugendpsychiatrie Practice Questions

Prepare for the Facharzt FMH für Kinder- und Jugendpsychiatrie und -psychotherapie / Spécialiste FMH en psychiatrie et psychothérapie d'enfants et d'adolescents exam with instant access — no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately
100+ Questions
100% Free

Loading practice questions...

2026 Statistics

Key Facts: Facharzt FMH Kinder- und Jugendpsychiatrie Exam

Written + Oral

Exam Format

SGKJPP / SIWF Examination Regulations

60–90 min

Oral Colloquium

SGKJPP Examination Committee

6 Years

Postgraduate Training

SIWF Weiterbildungsprogramm

Lifetime

FMH Title Validity

Swiss Medical Association (FMH)

CHF 1,550

Exam Fee

SGKJPP Regulations

100

Practice Questions

OpenExamPrep

The Facharzt FMH Kinder- und Jugendpsychiatrie und -psychotherapie credential certifies specialist child and adolescent psychiatrists in Switzerland through SIWF and SGKJPP. Assessment comprises a written clinical case presentation and an oral-practical colloquium with video case analysis, covering neurodevelopment, mood and eating disorders, psychotherapies, psychopharmacology, and Swiss child protection law.

Sample Facharzt FMH Kinder- und Jugendpsychiatrie Practice Questions

Try these sample questions to test your Facharzt FMH Kinder- und Jugendpsychiatrie exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1An 8-year-old boy is brought to the child psychiatric clinic due to persistent inattention, motor restlessness, and impulsive behavior in both school and home environments lasting for over 18 months. His teacher reports frequent blurting out of answers, inability to wait his turn, and difficulty sustaining attention during academic tasks. Physical examination, hearing, and vision are normal. According to current European (ESCAP) guidelines and the Multiaxial Classification Scheme (MAS), which of the following is the first-line pharmacotherapeutic agent when moderate-to-severe functional impairment persists despite psychoeducation and behavioral classroom accommodations?
A.Methylphenidate
B.Atomoxetine
C.Guanfacine extended-release
D.Clonidine
Explanation: Methylphenidate is the evidence-based first-line psychostimulant for school-aged children with moderate-to-severe Attention-Deficit/Hyperactivity Disorder (ADHD). It acts by blocking the dopamine transporter (DAT) and norepinephrine transporter (NET), significantly improving core symptoms of inattention, hyperactivity, and impulsivity. Non-stimulants such as atomoxetine or guanfacine are typically reserved for second-line therapy or when stimulants are contraindicated or not tolerated.
2A 9-year-old girl is evaluated for suspected Attention-Deficit/Hyperactivity Disorder (ADHD). Before initiating treatment with a psychostimulant such as osmotic-release oral system (OROS) methylphenidate, which pre-therapeutic baseline diagnostic assessment is mandatory according to Swiss and European clinical standards?
A.Routine 24-hour ambulatory electroencephalography (EEG) and brain magnetic resonance imaging (MRI)
B.Cardiovascular history (including personal/family history of syncope or sudden unexplained cardiac death), baseline blood pressure, heart rate, height, and weight percentiles
C.Serial serum prolactin, thyroid-stimulating hormone (TSH), and fasting lipid panel
D.Comprehensive neuropsychological test battery (e.g., WISC-V) demonstrating a specific deficit in executive function
Explanation: Prior to starting psychostimulant pharmacotherapy, guidelines mandate a comprehensive personal and family cardiovascular evaluation (screening for sudden unexplained cardiac death under age 40, syncope, palpitations, or congenital heart disease), alongside baseline measurements of blood pressure, resting heart rate, height, and body weight plotted on standardized percentiles. Routine ECG is recommended if there is a positive personal/family cardiac history or abnormal cardiac auscultation.
3A 10-year-old boy diagnosed with ADHD combined presentation has shown inadequate clinical response and severe late-afternoon rebound irritability on optimal doses of immediate-release and extended-release methylphenidate formulations. The treating child psychiatrist considers switching to lisdexamfetamine. What pharmacokinetic mechanism distinguishes lisdexamfetamine from conventional dextroamphetamine formulations?
A.It is an inactive prodrug converted to active d-amphetamine in the liver via cytochrome P450 CYP2D6 metabolism
B.It relies exclusively on gastric acid cleavage, resulting in pH-dependent erratic gastrointestinal absorption
C.It is an inactive prodrug that is enzymatic cleaved by red blood cell aminopeptidases, providing rate-limited, gradual systemic release of d-amphetamine and reduced abuse potential
D.It undergoes rapid first-pass esterase cleavage in the intestinal lumen, producing an immediate high plasma peak concentration
Explanation: Lisdexamfetamine dimesylate is a pharmacologically inactive prodrug wherein d-amphetamine is covalently linked to the essential amino acid L-lysine. Following absorption in the gastrointestinal tract, lisdexamfetamine is enzymatically hydrolyzed by cytosolic aminopeptidases in red blood cells to yield active d-amphetamine and L-lysine. This enzymatic conversion is rate-limited and independent of gastrointestinal pH, resulting in smooth, predictable pharmacokinetics, extended duration of action, and low potential for parenteral diversion or abuse.
4A 4-year-old child is referred for developmental evaluation due to absent communicative speech, lack of eye contact, failure to respond to his name, and intense repetitive lining up of toy cars. He becomes extremely distressed when daily routines are slightly altered. Which semi-structured, standardized assessment tool is considered the gold-standard direct observational instrument for diagnosing Autism Spectrum Disorder (ASD)?
A.Child Behavior Checklist (CBCL)
B.Conners-3 Parent and Teacher Rating Scales
C.Wechsler Intelligence Scale for Children (WISC-V)
D.Autism Diagnostic Observation Schedule, Second Edition (ADOS-2)
Explanation: The Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) is the internationally recognized gold-standard standardized observational assessment for Autism Spectrum Disorder across ages, developmental levels, and language skills. Combined with the Autism Diagnostic Interview-Revised (ADI-R) with caregivers, it provides comprehensive diagnostic validity.
5A 12-year-old boy with Autism Spectrum Disorder (level 2 support needs) presents with severe, escalating behavioral outbursts, property destruction, and severe physical aggression toward caregivers whenever tasks are demanded. Thorough behavioral functional analysis, environmental modifications (TEACCH structure), and visual communication supports have yielded insufficient improvement. Which psychotropic medications have official regulatory approval (Swissmedic / FDA) for the treatment of severe irritability and aggression associated with ASD in children and adolescents?
A.Risperidone and Aripiprazole
B.Haloperidol and Chlorpromazine
C.Fluoxetine and Citalopram
D.Methylphenidate and Modafinil
Explanation: Risperidone and Aripiprazole are the two atypical (second-generation) antipsychotics with regulatory approval for the treatment of severe irritability, aggression, temper tantrums, and self-injurious behavior in children and adolescents with Autism Spectrum Disorder. Their use requires careful baseline and ongoing metabolic, prolactin, and extrapyramidal symptom monitoring.
6A 7-year-old boy presents with frequent eye-blinking, shoulder-shrugging, and head-jerking motor movements that have been present for 14 months. Over the past 4 months, he has also developed repetitive throat-clearing and involuntary grunting sounds. The symptoms wax and wane in intensity, worsen during stress, and are preceded by an uncomfortable premonitory urge. What is the definitive diagnosis according to DSM-5-TR and ICD-11 criteria?
A.Provisional Tic Disorder
B.Tourette Syndrome (Combined Vocal and Multiple Motor Tic Disorder)
C.Persistent (Chronic) Motor Tic Disorder
D.Stereotypic Movement Disorder
Explanation: Tourette Syndrome (Tourette Disorder) is diagnosed when both multiple motor tics and at least one vocal/phonic tic have been present at some time during the illness (though not necessarily concurrently), persisting for more than 1 year, with onset before 18 years of age, and not attributable to physiological effects of a substance or another medical condition.
7Which behavioral psychotherapy modality is established by European (ESCAP) and American (AACAP) clinical guidelines as the first-line psychosocial treatment for children with Tourette Syndrome and Chronic Tic Disorders?
A.Psychoanalytic play therapy
B.Systemic paradoxical intention
C.Comprehensive Behavioral Intervention for Tics (CBIT) including Habit Reversal Training (HRT)
D.Dialectical Behavior Therapy for Children (DBT-C)
Explanation: Comprehensive Behavioral Intervention for Tics (CBIT), incorporating Habit Reversal Training (HRT) and Exposure and Response Prevention (ERP), is the gold-standard, first-line behavioral therapy for tic disorders. It consists of awareness training (recognizing the premonitory urge) and competing response training (initiating a physically incompatible voluntary muscle contraction), combined with functional environmental interventions.
8A 9-year-old child with Tourette syndrome and comorbid ADHD requires pharmacotherapy because tics cause physical neck pain and severe classroom disruption, and behavioral therapy is unavailable locally. Which pharmacological agent is particularly advantageous in this clinical scenario because it treats both ADHD and tic symptoms without worsening tics?
A.Atomoxetine
B.Methylphenidate immediate release
C.Haloperidol
D.Guanfacine extended-release (selective alpha-2A agonist)
Explanation: Guanfacine extended-release (an alpha-2A adrenergic receptor agonist) is especially valuable in patients presenting with comorbid ADHD and tic disorders / Tourette syndrome. By stimulating postsynaptic alpha-2A receptors in the prefrontal cortex, it improves attention, impulse control, and executive function while simultaneously reducing tic frequency and severity.
9An 8-year-old boy of normal intelligence (WISC-V Full Scale IQ = 108) exhibits severe, persistent difficulties with word reading accuracy, slow and effortful reading rate, and poor spelling. Phonological awareness tasks show marked deficits in phonemic segmentation and blending. His vision and hearing are intact, and he has received adequate formal schooling. According to ICD-11 (code 6A03) and MAS Axis 2 classification, what is the primary diagnosis?
A.Developmental Language Disorder with impairment of receptive language
B.Attention-Deficit/Hyperactivity Disorder, predominantly inattentive type
C.Developmental Learning Disorder with impairment in reading (Developmental Dyslexia)
D.Mild Intellectual Developmental Disorder
Explanation: Developmental Learning Disorder with impairment in reading (Developmental Dyslexia; ICD-11: 6A03.0; MAS Axis 2) is characterized by significant and persistent difficulties in learning academic skills related to reading, such as word reading accuracy, reading fluency, and reading comprehension, that are substantially below what is expected for chronological age and general intellectual functioning, and not better explained by sensory impairment, intellectual disability, or inadequate instruction.
10A 5-year-old boy speaks fluently, spontaneously, and with age-appropriate vocabulary at home with his parents and siblings. However, for the past 6 months since enrolling in kindergarten, he has never spoken a single word to teachers or peers, instead relying on nodding or pointing. His hearing and receptive language comprehension are normal. What is the most likely psychiatric diagnosis?
A.Developmental Speech Sound Disorder
B.Selective Mutism
C.Childhood-Onset Fluency Disorder (Stuttering)
D.Autism Spectrum Disorder
Explanation: Selective Mutism is characterized by a consistent failure to speak in specific social situations where there is an expectation to speak (e.g., school/kindergarten), despite speaking normally in other situations (e.g., at home with immediate family). The disturbance must last for at least 1 month (not limited to the first month of school) and interferes with educational or social communication.

About the Facharzt FMH Kinder- und Jugendpsychiatrie Exam

The Facharzt FMH für Kinder- und Jugendpsychiatrie und -psychotherapie (Specialist in Child and Adolescent Psychiatry and Psychotherapy FMH) is the Swiss Federal specialist medical title granting full independent practice rights in child and adolescent psychiatry and psychotherapy across Switzerland. Governed by the SIWF (Swiss Institute for Postgraduate and Continuous Medical Training) and the SGKJPP / SSPPEA (Swiss Society for Child and Adolescent Psychiatry and Psychotherapy), certification requires completion of a 6-year accredited postgraduate residency, comprehensive psychotherapeutic training (theory, supervision, and self-experience), submission of a scientific written clinical case study (Kasuistik), and passing a structured oral-practical colloquium with video case analysis. The curriculum encompasses neurodevelopmental disorders (ADHD, ASD, tics, learning disabilities), pediatric mood and anxiety disorders, eating disorders (anorexia nervosa, bulimia, ARFID), psychological trauma and attachment disorders, psychotic and disruptive disorders, evidence-based psychotherapy modalities (CBT, systemic family therapy, DBT-A, psychodynamic play therapy), child/adolescent psychopharmacology, and Swiss legal and child protection frameworks (KESB, Art. 314c ZGB, Fürsorgerische Unterbringung FUB Art. 426 ZGB, Urteilsfähigkeit Art. 16 ZGB). Note on format and language: While the official Swiss examination is administered in national languages (German or French) consisting of a written case presentation and oral-practical colloquium, this question bank is an English-language multiple-choice study adaptation created by OpenExamPrep—not an official SGKJPP/SIWF exam release—specifically designed to test and consolidate clinical decision-making, psychopharmacological mechanisms, therapeutic interventions, and Swiss statutory standards.

Assessment

Two-part specialty board examination: 1) Written clinical case study (detailed psychotherapeutic and psychiatric diagnostic/treatment case report adhering to scientific guidelines), and 2) Structured oral-practical examination before the SGKJPP board evaluating real-world video case vignettes, psychotherapeutic interventions, differential diagnosis, emergency management, and Swiss legal frameworks.

Time Limit

Written case portfolio preparation plus 60–90 minutes oral clinical examination

Passing Score

Formal passing grade on the written case monograph and consensus passing evaluation by the SGKJPP examination committee across all oral clinical domains

Exam Fee

SGKJPP examination fee ~CHF 1,550; SIWF title issuance fee ~CHF 1,000–2,500; postgrad psychotherapy theory/supervision ~CHF 15,000–25,000 (often subsidized by employing clinics) (Schweizerisches Institut für ärztliche Weiter- und Fortbildung (SIWF / FMH) & Schweizerische Gesellschaft für Kinder- und Jugendpsychiatrie und -psychotherapie (SGKJPP / SSPPEA))

Facharzt FMH Kinder- und Jugendpsychiatrie Exam Content Outline

22%

Neurodevelopmental Disorders (ADHD, ASD, Tics & Learning Disabilities)

Evidence-based diagnostic criteria, neurobiology, multiaxial classification, psychometric testing (ADOS-2, ADI-R, WISC-V, Conners-3), multimodal treatment algorithms (behavioral parent training, school accommodations), and psychopharmacotherapy (methylphenidate, lisdexamfetamine, atomoxetine, guanfacine, aripiprazole) for Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Tourette syndrome/chronic tics, communication disorders, specific learning disorders (dyslexia, dyscalculia), and intellectual developmental disabilities.

20%

Pediatric Mood, Anxiety, Obsessive-Compulsive & Stress-Related Disorders

Clinical assessment, differential diagnosis, developmental phenomenology, psychotherapy modalities (CBT, ERP, IPT-A), and pharmacotherapy (fluoxetine, sertraline, escitalopram, lithium, second-generation antipsychotics) for pediatric major depressive disorder, disruptive mood dysregulation disorder (DMDD), pediatric bipolar disorder, generalized anxiety, social phobia, panic disorder, agoraphobia, separation anxiety, selective mutism, and obsessive-compulsive disorder (OCD).

18%

Eating Disorders, Trauma, Attachment & Somatoform Disorders

Inpatient and outpatient management of anorexia nervosa (medical stabilization, refeeding syndrome prevention, electrolyte monitoring, family-based treatment FBT), bulimia nervosa, ARFID, binge-eating disorder; assessment and evidence-based psychotherapy for acute stress disorder, PTSD, complex developmental trauma (TF-CBT, EMDR, KidNET), attachment disorders (reactive attachment disorder RAD, disinhibited social engagement disorder DSED), functional neurological disorder / conversion, somatic symptom and chronic pain disorders.

16%

Psychotic Disorders, Personality Emergence & Substance Use Disorders

Early identification and intervention for first-episode psychosis and early-onset schizophrenia (EOS), attenuated psychosis syndrome, medical and autoimmune mimics (anti-NMDAR encephalitis, Wilson disease, 22q11.2 deletion syndrome), second-generation antipsychotic titration and metabolic/cardiac monitoring, conduct disorder (CD) and callous-unemotional traits, oppositional defiant disorder (ODD), emerging borderline and emotionally unstable personality traits in adolescence (DBT-A, MBT-A), and adolescent substance use disorders (cannabis-induced psychosis, alcohol intoxication, behavioral/gaming addictions).

12%

Psychotherapy Modalities, Systemic Family Interventions & Pharmacotherapy Principles

Theoretical foundations and clinical application of cognitive behavioral therapy (CBT), systemic family therapy (structural and circular interventions, multi-family therapy), dialectical behavior therapy for adolescents (DBT-A), psychodynamic child and adolescent psychotherapy (play therapy, transference, defense mechanisms), behavioral parent management training (PMT, Triple P, Incredible Years), Swissmedic approval status vs off-label psychopharmacology in minors, therapeutic drug monitoring (TDM), and ECG/QTc/endocrine monitoring protocols.

12%

Swiss Child Protection Law, Ethics, Forensic & Emergency Interventions

Swiss Civil Code (ZGB) provisions governing child protection (Kindesschutz, KESB child endangerment reporting under Art. 314c/314d ZGB, medical confidentiality Art. 321 StGB exemptions), involuntary hospitalization / Fürsorgerische Unterbringung (FUB Art. 426–439 ZGB in minors), capacity to consent / Urteilsfähigkeit (Art. 16 ZGB) and adolescent medical autonomy, acute crisis de-escalation, emergency psychopharmacology for acute agitation, assessment and safety planning for acute suicidality and non-suicidal self-injury (NSSI), and forensic assessment of child physical/sexual abuse and neglect.

How to Pass the Facharzt FMH Kinder- und Jugendpsychiatrie Exam

What You Need to Know

  • Passing score: Formal passing grade on the written case monograph and consensus passing evaluation by the SGKJPP examination committee across all oral clinical domains
  • Assessment: Two-part specialty board examination: 1) Written clinical case study (detailed psychotherapeutic and psychiatric diagnostic/treatment case report adhering to scientific guidelines), and 2) Structured oral-practical examination before the SGKJPP board evaluating real-world video case vignettes, psychotherapeutic interventions, differential diagnosis, emergency management, and Swiss legal frameworks.
  • Time limit: Written case portfolio preparation plus 60–90 minutes oral clinical examination
  • Exam fee: SGKJPP examination fee ~CHF 1,550; SIWF title issuance fee ~CHF 1,000–2,500; postgrad psychotherapy theory/supervision ~CHF 15,000–25,000 (often subsidized by employing clinics)

Keys to Passing

  • Work through all 100 available questions
  • Review every answer and explanation
  • Track weak areas and revisit them
  • Use our AI tutor for tough concepts

Facharzt FMH Kinder- und Jugendpsychiatrie Study Tips from Top Performers

1Master the Multiaxial Classification Scheme (MAS): Ensure thorough fluency in evaluating all 6 axes (Axis 1: Clinical psychiatric syndrome; Axis 2: Specific developmental disorders; Axis 3: Intellectual level; Axis 4: Somatic conditions; Axis 5: Psychosocial stressors; Axis 6: Global psychosocial functioning).
2Understand Pediatric Psychopharmacology & Monitoring: Memorize baseline screening requirements (cardiac history, pulse, BP, growth percentiles for stimulants; ECG/QTc intervals for antipsychotics; metabolic panels and prolactin for second-generation antipsychotics; lithium blood levels, renal, and thyroid function).
3Know Evidence-Based Psychotherapy Indications: Differentiate first-line psychotherapy indications across disorders (CBT with ERP for OCD and anxiety; Family-Based Treatment FBT for adolescent anorexia nervosa; TF-CBT and EMDR for PTSD; Parent Management Training for ODD; DBT-A for borderline traits and chronic NSSI).
4Navigate Swiss Child Protection (KESB & ZGB): Master the legal conditions for filing a Gefährdungsmeldung under Art. 314c ZGB (relieving medical confidentiality), requirements for FUB involuntary placement under Art. 426 ff. ZGB in minors, and the assessment of Urteilsfähigkeit (Art. 16 ZGB) in adolescents.
5Review Medical Mimics & Organic Differential Diagnoses: Be prepared to identify somatic causes of acute psychiatric symptoms in children, including autoimmune encephalitis (anti-NMDAR), Wilson disease, acute intermittent porphyria, 22q11.2 deletion syndrome, metabolic inborn errors, and substance-induced presentations.

Frequently Asked Questions

What is the Facharzt FMH für Kinder- und Jugendpsychiatrie und -psychotherapie title?

The Facharzt FMH für Kinder- und Jugendpsychiatrie und -psychotherapie is the federally recognized Swiss specialist medical title awarded by the SIWF / FMH. It certifies full professional competence to independently diagnose and treat psychiatric, developmental, emotional, and behavioral disorders in children, adolescents, and their families, using psychiatric, psychopharmacological, and psychotherapeutic modalities.

How is the official Swiss Child & Adolescent Psychiatry specialist examination structured?

The examination conducted by the SGKJPP / SSPPEA consists of two main components: 1) A written scientific clinical case monograph (Kasuistik) documenting the thorough assessment, differential diagnosis, evidence-based psychotherapy, and systemic management of a complex clinical case, and 2) A structured oral-practical colloquium before an expert examination committee involving video case analysis, discussion of the submitted case, and examination of broad psychiatric and psychotherapeutic knowledge.

What are the postgraduate training duration and requirements for the title?

The total training duration is 6 years of accredited residency: 4 years in child and adolescent psychiatry and psychotherapy (including inpatient and outpatient care), 1 year in adult psychiatry and psychotherapy, and 1 year in clinical somatic medicine (such as pediatrics, neurology, neuropediatrics, or internal medicine). In addition, candidates must complete 240 hours of psychotherapy theory, 150 hours of supervision, and 100 hours of self-experience (Selbsterfahrung).

What Swiss legal frameworks are essential for child and adolescent psychiatrists?

Essential legal frameworks include the Swiss Civil Code (ZGB) provisions for child protection (Kindesschutz) and reporting to KESB (Kindes- und Erwachsenenschutzbehörde) under Art. 314c ZGB, involuntary psychiatric hospitalization (Fürsorgerische Unterbringung FUB under Art. 426–439 ZGB), capacity of judgement and medical consent (Urteilsfähigkeit under Art. 16 ZGB), and medical professional confidentiality under Art. 321 StGB.

Why is this practice question bank provided in English?

While the official Swiss specialty examination is conducted in Swiss national languages (German or French), international scientific child and adolescent psychiatric literature, clinical research, psychopharmacology guidelines (ESCAP, AACAP), and diagnostic classifications are predominantly English-based. This practice bank adapts core SGKJPP and SIWF curriculum standards into 100 high-yield English-language questions.

What are the first-line psychopharmacological treatments in child and adolescent psychiatry?

For ADHD, psychostimulants (methylphenidate, lisdexamfetamine) are first-line, followed by non-stimulants (atomoxetine, guanfacine). For moderate-to-severe pediatric depression and anxiety/OCD, SSRIs (specifically fluoxetine for depression, and sertraline/fluoxetine for OCD) are first-line in combination with CBT. Second-generation antipsychotics (aripiprazole, risperidone) are approved for severe irritability in autism or early-onset schizophrenia, requiring strict metabolic and ECG monitoring.